Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data

Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data

Sep 13, 2017
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-cosentyx-sets-new-benchmark-psoriasis-robust-5-year-sustained-efficacy-and-safety-phase-iii-data-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-cosentyx-sets-new-benchmark-psoriasis-robust-5-year-sustained-efficacy-and-safety-phase-iii-data-0